None
 Not to mention each one gets a “Strong Buy” consensus rating from the analyst community.9 Meters Biopharma (NMTR)Some biopharma companies take a broad-based approach, while others focus on a niche.
With 4 Buys and no Holds or Sells, the word on the Street is that NMTR is a Strong Buy.
Given its $4.33 average price target, upside of 386% could be in store for investors.
Buy), and his $15 price target indicates a potential for 241% growth in the year ahead.
At $15, the average price target indicates shares could appreciate by 241% in the year ahead.